ClinicalTrials.gg
Not yet recruitingNCT07920627EpiCEUpdated Nov 5, 2026

Epidemiology of Clostridioides Difficile Infection (CDI) in Long-term Care Facilities, Assessment of Professional Practices Related to CDI Risk Prevention, and Strategies for Improving Care.

An observational study in Clostridioides Difficile Infection, sponsored by Assistance Publique Hopitaux De Marseille. Not yet recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Assistance Publique Hopitaux De Marseille · Observational

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
65 Years and older
Sex
All
01

Study summary

Clostridioides difficile infection (CDI) is the leading cause of infectious diarrhea among older adults. The epidemiology of community-acquired CDI, particularly among residents of long-term care facilities, remains poorly understood to this day. While numerous studies on the epidemiology, prevention, diagnosis, and treatment of CDI have been conducted in hospital settings, primary care often lags behind these advances. Limited access to diagnostic tests and treatment options, as well as insufficient resources allocated to preventing cross-transmission, are all factors that hinder the control of ICD in long-term care facilities. This will be the first French study on the epidemiology of ICD among nursing home residents, which can serve as a reference for implementing a multidisciplinary action plan and measuring its impact. This will be carried out as part of a city-hospital collaboration and will facilitate the creation of a healthcare network involving multiple healthcare providers, such as general practitioners working in nursing homes, clinical laboratories, pharmacies, dietitians and nutritionists, and the university hospital.

A better understanding of the epidemiology of ICD among residents in long-term care facilities and an assessment of professional practices related to ICD risk prevention should enable us to better target strategies for improving care while raising awareness among healthcare providers and public health policymakers. We therefore plan to optimize the impact of implementing a multidisciplinary action program aligned with the expectations of frontline practitioners regarding the reduction of the risk of ICD (training, prevention tools, diagnosis and treatment of ICD, appropriate use of antibiotics, nutritional counseling, prescribing probiotics, and establishing a coordinated care pathway for ICD). The implementation of this action program is expected to reduce the incidence rate of ICD, the recurrence rate, and antibiotic use in nursing homes, as well as the number of transfers to the hospital for ICD management.

02

Conditions studied

  • Clostridioides Difficile Infection
03

In context

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 226 across 52 observational studies indexed under Clostridium Infections.

Browse Clostridium Infections studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

residents of nursing homes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 65 or older
  • Patients who have received information about the study and have not expressed objection
  • Residents of the nursing home for more than 72 hours during the 12-month enrollment period
  • No objection to the use of clinical and biological data in the event of an ICD.

Exclusion criteria

Exclusion Criteria:

  • A patient who is in the exclusion period of another research protocol at the time the form is obtained.
  • A person who does not understand French
  • No inclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence Rate of ICD

    * Probable C. difficile infection: diarrhea (\>3 loose stools per 24 hours) within two months of taking an antibiotic or within 72 hours of hospitalization. * Confirmed C. difficile infection: diarrhea AND detection of Clostridioides difficile toxins.

    Time frame: 24 MONTHS

Secondary outcomes

  1. the recurrence rate of C. difficile colitis

    Time frame: 24 MONTHS

  2. Measuring the Use of Critical Antibiotics

    Time frame: 24 MONTHS

  3. Measure the number of hospital transfers for ICD management.

    Time frame: 24 MONTHS

  4. the prevalence of the main risk factors for ICD

    Time frame: 24MONTHS

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07920627
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

cassir nadim
principal investigator · assistance publique hôpitaux de Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion